Calamos Advisors
AZN icon

Calamos Advisors’s AstraZeneca AZN Stock Holding History

Calamos Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,550
Closed -$4.84M – 1210
2025
Q4 		$4.84M Sell
31,550
-21,250
-40% -$3.73M 0.02% 536
2025
Q3 		$7.38M Buy
+52,800
New +$7.99M 0.03% 476

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Calamos Advisors's AZN Position: Q1 2026 in Review

Calamos Advisors increased its AstraZeneca (AZN) stake by 424% in Q1 2026, buying an estimated $5.27M and bringing the position to 33,768 shares worth $6.66M. The position accounts for 0.02% of the portfolio, ranked #497.

Calamos Advisors first reported a position in AZN in Q3 2018 and has held it in 14 quarters since. The position peaked at $17.8M in Q3 2021. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Calamos Advisors held 33,768 shares of AstraZeneca worth $6.66M as of Q1 2026.
  • Calamos Advisors bought 27,329 AstraZeneca shares in Q1 2026, an estimated $5.27M.
  • AstraZeneca made up 0.02% of Calamos Advisors's portfolio in Q1 2026, its #497 holding.
  • Calamos Advisors first reported a position in AstraZeneca in Q3 2018 and has held it in 14 quarters since.
  • Calamos Advisors's AstraZeneca position peaked at $17.8M in Q3 2021.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.